Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy

Abstract

Immunotherapy is a promising modality of treatment for cancer. Immunotherapy is comprised of systemic and local treatments that induce an immune response, allowing the body to fight back against cancer. Systemic treatments such as cancer vaccines harness antigen presenting cells (APCs) to activate T cells with tumor-associated antigens. Small molecule inhibitors can be employed to inhibit immune checkpoints, disrupting tumor immunosuppression and immune evasion. Despite the current efficacy of immunotherapy, improvements to delivery can be made. Nanomaterials such as mesoporous silica can facilitate the advancement of immunotherapy. Mesoporous silica has high porosity, decent biocompatibility, and simple surface functionalization. Mesoporous silica can be utilized as a versatile carrier of various immunotherapeutic agents. This review gives an introduction on mesoporous silica as a nanomaterial, briefly covering synthesis and biocompatibility, and then an overview of the recent progress made in the application of mesoporous silica to cancer immunotherapy.

Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy

“…The MSNs with sizes ranging from 100 to 200 nm were thought to be relatively safe according to a previous publication. 36…”

“…The MSNs with sizes ranging from 100 to 200 nm were thought to be relatively safe according to a previous publication. 36 To quantify the Mn amount doped into MSNs, ICP-AES analysis was performed. As shown in Table 3, the mass concentrations of Mn in MSNs, MM1, and MM2 were 0, 13.9 AE 3.1%, and 24.9 AE 1.1%, respectively.…”

Silica‐based Nanoparticles for Enzyme Immobilization and Delivery

“…[45,46] Thus, a wide variety of SNPs are available to meet the needs of diverse applications in many fields. Ever since the early days of the development of SNPs, researchers had spotted the potential of SNPs in biomedical applications, [47][48][49] especially as nanocarriers for biomolecules delivery. Recent developments of SNPs are not just limited to precise control of their structures, compostions and surface modifications.…”

Correction: Yu et al. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109

“…In the published publication [ 1 ], there was an error regarding the affiliation(s) for Albert Yu, Xiaoyong Dai, Zixian Wang, Huaqing Chen, and Laiqiang Huang . In addition to affiliations 1, 2 and 3 , the updated affiliations should include: 1.…”